Invesco Capital Management LLC recently announced the acquisition of new stake in InflaRx N.V. (NASDAQ:IFRX). The institutional investor has increased its shareholding in the Healthcare company by 145.37% to 0.27 million shares with purchase of 0.16 million shares. This fresh investment now brings its stake to 0.61% valued currently at $0.84 million. In addition, Susquehanna Financial Group LLLP raised its holdings by 1428.0 to 48178.0 shares.
With over 0.1 million InflaRx N.V. (IFRX) shares trading Monday and a closing price of $2.33 on the day, the dollar volume was approximately $0.24 million. The shares have shown a positive half year performance of 72.59% and its price on 01/23/23 lost nearly -3.12%. Currently, there are 44.20M common shares owned by the public and among those 37.62M shares have been available to trade.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for IFRX have a consensus price objective of $4.88. The analysts have set the share’s price value over the next 12 months at a high of $7.98 and a low of $1.99. The average price target is 53.4% above its recent price level and a downside to the estimated low will see the stock lose -17.09% over that period. But an upside of 70.8% will see the stock hit the forecast high price target while median target price for the stock is $4.77.
The top 3 mutual fund holders in InflaRx N.V. are Diversified Growth Company – Notz, Invesco Raymond James SB-1 Equity, and WEALTHGATE Biotech Aggressive Fun. Diversified Growth Company – Notz owns 74062.0 shares of the company’s stock, all valued at over $0.23 million. The company bought an additional 35979.0 shares recently to bring their total holdings to about 0.17% of the shares outstanding. WEALTHGATE Biotech Aggressive Fun bought 25000.0 shares to bring its total holdings to over 30570.0 shares at a value of $94767.0. WEALTHGATE Biotech Aggressive Fun now owns shares totaling to 0.07% of the shares outstanding.
Shares of InflaRx N.V. (NASDAQ: IFRX) opened at $2.43, up $0.03 from a prior closing price of $2.40. However, the script later moved the day high at 2.5000, down -3.12%. The company’s stock has a 5-day price change of -11.41% and -4.90% over the past three months. IFRX shares are trading -24.84% year to date (YTD), with the 12-month market performance down to -38.85% lower. It has a 12-month low price of $0.78 and touched a high of $3.81 over the same period. IFRX has an average intraday trading volume of 106.73K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -16.55%, -9.70%, and 8.39% respectively.
Institutional ownership of InflaRx N.V. (NASDAQ: IFRX) shares accounts for 9.50% of the company’s 44.20M shares outstanding. Mutual fund holders own 0.42%, while other institutional holders and individual stakeholders account for 8.62% and — respectively.
It has a market capitalization of $102.99M and a beta (3y monthly) value of 0.93. The earnings-per-share (ttm) stands at -$0.83. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.60% over the week and 10.92% over the month.
Analysts forecast that InflaRx N.V. (IFRX) will achieve an EPS of -$0.33 for the current quarter, -$0.33 for the next quarter and -$0.82 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.36 while analysts give the company a high EPS estimate of -$0.24. Comparatively, EPS for the current quarter was -$0.31 a year ago. Earnings per share for the fiscal year are expected to increase by 12.70%, and -15.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate InflaRx N.V. (IFRX) as a “Moderate Buy” at a consensus score of 2.30. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 1 of the 5 advise that investors “hold,” and 1 rated it as a “Sell.”
Raymond James coverage for the InflaRx N.V. (IFRX) stock in a research note released on October 28, 2021 offered a Strong Buy rating with a price target of $14. Guggenheim was of a view on March 11, 2021 that the stock is Buy, while SVB Leerink gave the stock Outperform rating on November 06, 2020, issuing a price target of $7- $10. H.C. Wainwright on their part issued Buy rating on October 08, 2020.
